Ind-Swift Labs Reports Negative Performance in Q1 2024 Financial Results

Ind-Swift Laboratories, a microcap pharmaceutical company, recently announced its financial results for the quarter ending June 2024. The company's stock has been given a 'Sell' call by MarketsMOJO.

According to the financial report, Ind-Swift Labs has seen a negative performance in the quarter, with a score of -11 compared to 5 in the previous quarter. This decline can be attributed to several factors.

One of the major concerns is the company's net sales, which have fallen by 89.31% year on year, standing at Rs 33.17 crore. This indicates a very negative trend in the near term. Similarly, the profit before tax (PBT) has also decreased by 139.03% year on year, with a value of -10.16 crore. The profit after tax (PAT) has also seen a decline of 94.5% year on year, with a value of 0.94 crore.

The company's ability to manage interest payments has also deteriorated, with the operating profit to interest ratio being the lowest in the last five quarters at -57.29 times. The net sales and operating profit (PBDIT) have also hit their lowest points in the last five quarters, indicating a negative trend in the near term.

The operating profit margin has also decreased to -29.36%, showing a decline in the company's efficiency. The PBT has also hit its lowest point in the last five quarters, standing at -10.16 crore. Additionally, the company's non-operating income is 1,136.73% of the PBT, which suggests that the company's income from non-business activities is high, which may not be a sustainable business model.

Lastly, the earnings per share (EPS) have also decreased to its lowest point in the last five quarters, standing at Rs 0.16. This decline in profitability has resulted in lower earnings for shareholders.

Overall, the financial results for the quarter ending June 2024 have not been favorable for Ind-Swift Laboratories. The company will need to address these issues and make necessary changes to improve its performance in the future.